<DOC>
	<DOC>NCT00018278</DOC>
	<brief_summary>The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.</brief_summary>
	<brief_title>Electrophysiologic Measures of Treatment Response in Alzheimer Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Patients diagnosed with mild to moderate probable Alzheimer's disease (minimental state exam scores between 1527), and normal controls (age generally between 6085). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2004</verification_date>
</DOC>